Specific immunotherapy in the treatment of atopic dermatitis;Spezifische immuntherapie bei der behandlung der atopischen dermatitis

Hautarzt

Volumn 58, Issue 3, 2007, Pages 232-236

  Niebuhr, M ^a   Kapp, A ^a   Werfel, T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Atopic dermatitis; Atopic eczema; Hyposensitization; IgE sensitization; Specific immunotherapy

Indexed keywords

ANTIALLERGIC AGENT; GAMMA INTERFERON; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; POLLEN ANTIGEN; STEROID;

ADAPTIVE IMMUNITY; ATOPIC DERMATITIS; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DERMATOPHAGOIDES; GRASS POLLEN; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LOCAL THERAPY; REVIEW; SENSITIZATION; STEROID THERAPY; TREATMENT INDICATION; TREATMENT OUTCOME;

DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 33947430081     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1220-x     Document Type: Review

References (36)

1. Akdis CA, Blesken T, Akdis M et al. (1998) Role of IL-10 in specific immunotherapy. J Clin Invest 102: 98-106
2. Akdis M, Verhagen A, Taylor A (2004) Immune responses in healthy and allergic individuals are characterized by a fine balance between allergenspecific T regulatory and T helper 2 cells. J Exp Med 199: 1567-1575
3. Akdis M, Blaser K, Akdis CA (2005) T regulatory cells in allergy: Novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 116: 961-968
4. Augustin M, Zschoke I (2001) Lebensqualität und Ökonomie bei allergischen Hauterkrankungen. Allergologie 24: 433-442
5. Bieber T (1997) Fc epsilon RI-expressing antigen-presenting cells: new players in the atopic game. Immunol Today 18: 311-313
6. Akdis CA, Akdis M, Bieber T et al. (2006) Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergy, Asthma and Immunology/PRACTALL Consensus report. J Allergy Clin Immunol 118: 152-169
7. Colombo S, Hill P, Shaw D et al. (2005) Effectiveness of low dose immunotherapy in the treatment of canine atopic dermatitis: a prospective, double-blinded, clinical study. Vet Dermatol 16: 162-170
8. Darsow U, Forer I, Ring J (2005) Spezifische Hyposensibilisierung bei atopischem Ekzem. Allergologie 2: 53-61
9. Di Prisco de Fuenmayor MC, Champion RH (1979) Specific hyposensitization in atopic dermatitis. Br J Dermatol 101: 697-700
10. Galli E, Chini L, Nardi S et al. (1994) Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol Immunopathol 22: 18-22
11. Jonuleit H, Schmitt E, Schuler G et al. (2000) Induction of Interleukin-10-producing, non-proliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192: 1213-1222
12. Jutel M, Akdis M, Budak F et al. (2003) IL-10 and TGF-β cooperate in regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33: 1205-1214
13. Kapp A (1995) Atopic dermatitis-the skin manifestation of atopy. Clin Exp Allergy 25: 210-219
14. Kleine-Tebbe J, Bergmann KC, Friedrichs F et al. (2006) Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J 15: 56-74
15. Leroy BP, Boden G, Lachapelle JM et al. (1993) A novel therapy for atopic dermatitis: a double-blind, placebo-controlled study. J Am Acad Dermatol 28: 232-239
16. Marshall JS, Leal-Berumen I, Nielsen L et al. (1996) Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J Clin Invest 97: 1122-1128
17. Mastrandrea F, Serio G, Minelli M et al. (2000) Specific sublingual immunotherapy in atopic dermatitis. Results of a 6 year follow-up of 35 consecutive patients. Allergol Immunopathol 28: 54-62
18. Mastrandrea F (2004) The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. Am J Clin Dermatol 5: 281-294
19. Michils A, Farber CM, Van Hooren JP (1994) Sustained benefit of Interferon-alpha therapy and oral hyposensitization in severe atopic dermatitis. Br J Dermatol 130: 134-135
20. Mosca M, Albani-Rocchetti G, Vignini MA et al. (1993) La vaccinoterapia sub-linguale nella dermatite atopica. G Ital Dermatol Venereol 128: 79-83
21. Novak N, Bieber T, Kraft S (2004) Immunglobulin E-bearing antigen-presenting cells in atopic dermatitis. Curr Allergy Asthma Rep 4: 263-269
22. Pacor ML, Biasi D, Malekina T (1994) The efficacy of long-term specific immunotherapy for Dermatophygoides pteronyssinus in patients with atopic dermatitis. Recenti Prog Med 85: 273-277
23. Pajno GB, Barberio G, De Luca F et al. (2001) Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 31: 1392-1397
24. Pajno GB, Peroni DG, Barberio G et al. (2003) Efficacy of sublingual immunotherapy in asthma and eczema. Chem Immunol Allergy 82: 77-88
25. Palma-Carlos AG, Spinola-Santos A, Ferreira MB et al. (2001) Immunotherapy in allergic rhinitis. Allerg Immunol 33: 323-326
26. Petrova SI, Berzhets VM, Albanova VI, et al. (2001) Immunotherapy in the complex treatment of patients with atopic dermatitis with sensitisation to house dust mites. Zh Mikrobiol Epidemiol Immunobiol 1: 33-36
27. Pichler CE, Helbling A, Pichler WJ (2001) Three years of specific immunotherapy house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of non-specific bronchial hyperreactivity. Allergy 56: 301-306
28. Ring J (1982) Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 107: 597-602
29. Schandane L, Alonso-Vega C, Willems F et al. (1994) B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol 152: 4368-4374
30. Schnabl B, Bettenay SV, Dow K et al. (2006) results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis. Vet Rec 158: 81-85
31. Silny W, Czarnecka-Operacz M (2006) Spezifische Immuntherapie bei der Behandlung von Patienten mit atopischer Dermatitis. Ergebnisse einer placebokontrollierten Doppelblindstudie. Allergologie 29: 171-183
32. Szucs T (1996) Sozioökonomische Aspekte der Neurodermitis in Deutschland. In: Riedl-Seifert R (Hrsg) München, S 49-65
33. Trimmer AM, Griffin C, Booerd M et al. (2005) Rush allergen specific immunotherapy protocol in feline atopic dermatitis: a pilot study of four cats. Veterinary Dermatology 16: 324-329
34. Werfel T, Morita A, Grewe M et al. (1996) Allergen specificity of skin infiltrating T cells is not restricted to a type 2 cytokine pattern in chronic skin lesions of atopic dermatitis. J Invest Dermatol 107: 871-876
35. Werfel T, Kapp A (1998) Environmental and other major provocation factors in atopic dermatitis. Allergy 53: 731-739
36. Werfel T, Breuer K, Rueff F et al. (2006) Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomised, dose-response study. Allergy 61: 202-205